Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma

Published:2022-06-13 Issue:7 Volume:42 Page:611-622
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Geynisman Daniel M.,Burotto Mauricio,Porta Camillo,Suarez Cristina,Bourlon Maria T.,Huo Stephen,Del Tejo Viviana,Du Ella X.,Yang Xiaoran,Betts Keith A.,Choueiri Toni K.,McGregor Bradley^ORCID

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-022-01170-6.pdf

Reference35 articles.

1. Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79–87. https://doi.org/10.14740/wjon1279.

2. Levitin M, Ofori J, Shin WJ, Huang J, Daly M, Cao D, et al. Radiation and checkpoint inhibitor immunotherapy lead to long term disease control in a metastatic RCC patient with brain metastases. Front Oncol. 2020. https://doi.org/10.3389/fonc.2020.566070.

3. National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER): Cancer Stat Facts: Kidney and Renal Pelvis Cancer. 2020. https://seer.cancer.gov/statfacts/html/kidrp.html. Accessed 13 Jan 2021.

4. Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90. https://doi.org/10.1056/NEJMoa1712126.

5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24. https://doi.org/10.1056/NEJMoa065044.